Catherine Thieblemont

Jan 8, 2025 | nature.com | Remy Duléry |Vincent Guiraud |Sylvain Choquet |Catherine Thieblemont |Emmanuel Bachy |Stéphane Barete | +3 more

AbstractThe risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018.

Nov 6, 2024 | nature.com | Adam S. Kittai |Antonio Gutierrez |Antonio Gutiérrez |Alejandro Martín García-Sancho |Monica D. Mead |Pere Barba | +2 more

The rationale for this project arises from some considerations. Clinical trials often use surrogate endpoints (response rates) rather than direct measurement of benefit (survivals) as primary objective of the study.

May 14, 2024 | nature.com | Roch Houot |Emmanuel Bachy |François-Xavier Gros |Catherine Thieblemont |Fabrice Jardin |Sylvain Choquet | +2 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02572-5, published online 14 September 2023In the version of the article initially published, the affiliation of Yassine Al Tabaa was incomplete and has now been updated to read “Scintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier, France” in the HTML and PDF versions of the article.

Oct 9, 2023 | nature.com | Roch Houot |Emmanuel Bachy |François-Xavier Gros |Catherine Thieblemont |Fabrice Jardin |Sylvain Choquet | +2 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02572-5, published online 14 September 2023.

Sep 14, 2023 | nature.com | Roch Houot |Emmanuel Bachy |Catherine Thieblemont |Fabrice Jardin |Sylvain Choquet |Karin Tarte | +2 more

AbstractAxicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem cell transplantation (ASCT); however, in clinical practice, roughly half of patients with R/R LBCL are deemed unsuitable candidates for ASCT. The efficacy of axi-cel remains to be ascertained in transplant-ineligible patients.